337 related articles for article (PubMed ID: 14685005)
1. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.
Bolton WK; Cattran DC; Williams ME; Adler SG; Appel GB; Cartwright K; Foiles PG; Freedman BI; Raskin P; Ratner RE; Spinowitz BS; Whittier FC; Wuerth JP;
Am J Nephrol; 2004; 24(1):32-40. PubMed ID: 14685005
[TBL] [Abstract][Full Text] [Related]
2. [Effect of lisinopril on progression of retinopathy and microalbuminuria in normotensive subjects with insulin-dependent diabetes mellitus].
Sjølie AK; Chaturvedi N; Fuller J
Ugeskr Laeger; 1999 Feb; 161(7):949-52. PubMed ID: 10051804
[TBL] [Abstract][Full Text] [Related]
3. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
4. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
Williams ME; Bolton WK; Khalifah RG; Degenhardt TP; Schotzinger RJ; McGill JB
Am J Nephrol; 2007; 27(6):605-14. PubMed ID: 17823506
[TBL] [Abstract][Full Text] [Related]
5. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective effects of a novel inhibitor of advanced glycation.
Forbes JM; Soulis T; Thallas V; Panagiotopoulos S; Long DM; Vasan S; Wagle D; Jerums G; Cooper ME
Diabetologia; 2001 Jan; 44(1):108-14. PubMed ID: 11206401
[TBL] [Abstract][Full Text] [Related]
7. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
Lewis EJ; Hunsicker LG; Bain RP; Rohde RD
N Engl J Med; 1993 Nov; 329(20):1456-62. PubMed ID: 8413456
[TBL] [Abstract][Full Text] [Related]
8. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
[TBL] [Abstract][Full Text] [Related]
9. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
[TBL] [Abstract][Full Text] [Related]
10. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; O'Brien RC; Raffaele J; Tsalamandris C;
Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085
[TBL] [Abstract][Full Text] [Related]
11. Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy.
Tamsma JT; van der Woude FJ; Lemkes HH
Nephrol Dial Transplant; 1996 Jan; 11(1):182-5. PubMed ID: 8649631
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
13. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
14. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).
Freedman BI; Wuerth JP; Cartwright K; Bain RP; Dippe S; Hershon K; Mooradian AD; Spinowitz BS
Control Clin Trials; 1999 Oct; 20(5):493-510. PubMed ID: 10503809
[TBL] [Abstract][Full Text] [Related]
15. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
Ravid M; Lang R; Rachmani R; Lishner M
Arch Intern Med; 1996 Feb; 156(3):286-9. PubMed ID: 8572838
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic interventions for nephropathy in type I diabetes mellitus.
Breyer JA
Semin Nephrol; 1997 Mar; 17(2):114-23. PubMed ID: 9148377
[TBL] [Abstract][Full Text] [Related]
17. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
[TBL] [Abstract][Full Text] [Related]
18. Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
Ivory SE; Packham DK; Reutens AT; Wolfe R; Rohde RD; Lewis J; Atkins RC;
Nephrology (Carlton); 2013 Jul; 18(7):516-24. PubMed ID: 23506627
[TBL] [Abstract][Full Text] [Related]
19. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
[TBL] [Abstract][Full Text] [Related]
20. Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens.
Chen KH; Lin JL; Lin-Tan DT; Hsu HH; Hsu CW; Hsu KH; Yen TH
Am J Kidney Dis; 2012 Oct; 60(4):530-8. PubMed ID: 22721929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
